A phase II trial with monoclonal antibody CG250 in advanced renal cell carcinoma.

被引：0
|
作者：
Varga, Z
Hegele, A
Hofmann, R
De Mulder, PD
Kruit, W
Warnaar, S
Mala, C
Ullrich, S
Huber, C
Lamers, C
Beck, J
机构：
来源：
JOURNAL OF UROLOGY | 2002年 / 167卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：192 / 193
页数：2
相关论文
共 50 条
  • [41] Phase II clinical trial of bevacizumab plus ixabepilone in renal cell carcinoma.
    Pichun, Mauricio Emmanuel Burotto
    Acquavella, Nicolas
    Edgerly, Maureen
    Bates, Susan Elaine
    Balasubramaniam, Sanjeeve
    Fojo, Antonio Tito
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [42] Fractionated radioimmunotherapy with I-131 chimeric antibody G250 (cG250) in metastatic renal cancer
    Divgi, CR
    O'Donoghue, JA
    McGagh, D
    Anwar, K
    Motzer, R
    Welt, S
    Larson, SM
    Old, LJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1158 - 1158
  • [43] Red marrow dosimetry after administration of I-131 labeled chimeric G250 monoclonal antibody (cG250) in patients with renal cell carcinoma, based on planar gamma camera images.
    Buijs, WCAM
    Steffens, MG
    Boerman, O
    Siegel, JA
    Oosterwijk, E
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 958 - 958
  • [44] Radioimmunotargeting with I-131 labeled chimeric G250 monoclonal antibody in patients with renal cell carcinoma.
    Steffens, MG
    Boerman, OC
    Oosterwijk, E
    Oosterhof, GON
    Witjes, JA
    OosterwijkWakka, JC
    Koenders, E
    Debruyne, FMJ
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (05) : 740 - 740
  • [45] Advanced renal cell carcinoma.
    Redman B.G.
    Chang A.E.
    Current Treatment Options in Oncology, 2000, 1 (5) : 417 - 422
  • [46] Phase II ECOG trial of atrasentan in advanced renal cell carcinoma
    Manola, J.
    Carducci, M.
    Nair, S.
    Liu, G.
    Rousey, S.
    Wilding, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Phase II trial of bortezomib for patients with advanced renal cell carcinoma
    Kondagunta, GV
    Drucker, B
    Schwartz, L
    Bacik, J
    Marion, S
    Russo, P
    Mazumdar, M
    Motzer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3720 - 3725
  • [48] Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Boers-Sonderen, Marye
    Muselaers, Stijn
    van Oostenbrugge, Tim
    Boerman, Otto
    Desar, Ingrid
    Stillebroer, Alexander
    Mulder, Sasja
    Van Herpen, Carla M. L.
    Langenhuijsen, Hans
    Oosterwijk, Egbert
    Oyen, Wim J. G.
    Mulders, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Phase II trial of thalidomide for patients with advanced renal cell carcinoma
    Motzer, RJ
    Berg, W
    Ginsberg, M
    Russo, P
    Vuky, J
    Yu, R
    Bacik, J
    Mazumdar, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 302 - 306
  • [50] Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Muselaers, Stijn
    Boers-Sonderen, Marye
    van Oostenbrugge, Tim
    Boerman, Otto
    Desar, Ingrid
    Stillebroer, Alexander
    Mulder, Sasja
    van Herpen, Carla
    Langenhuijsen, Johan
    Oosterwijk, Egbert
    Oyen, Wim
    Mulders, Peter
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
12345